Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06891742 | Phase I Study of OriC902 in Treatment of Advanced HCC | PHASE1 | RECRUITING | 44 | — | — | Feb 24, 2025 | Mar 31, 2028 | Mar 24, 2025 | 2 | China |
SRC will select MTD or biologically effective dose
SRC will select RP2D based on safety, initial efficacy (if any) and PK data
To evaluate the incidence and severity of AE and SAE
| Arm | Type | Description |
|---|---|---|
| OriC902 | EXPERIMENTAL | OriC902 injection, dosage is divided into 1E6/Kg, 3E6/ Kg, 6E6/Kg, 1E7/Kg |
| Name | Type | Description |
|---|---|---|
| OriC902 | DRUG | Whole peripheral blood mononuclear cells are extracted from patients (or donors) through leukocyte separation, and then the required T cell subsets are isolated, which will become the basis for the subsequent preparation of CAR T cells |
Inclusion Criteria: 1. Understand and voluntarily sign an informed consent form (ICF) prior to conducting any assessment/procedure related to the study; 2. Ages 18 to 75 at the time of signing the ICF (including 18 and 75); 3. HCC was diagnosed according to the Primary Liver Cancer Diagnosis and Tr...